Recent News

• 06.04.2025 - HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
• 06.02.2025 - HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting
• 05.23.2025 - HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting
• 04.24.2025 - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
• 04.22.2025 - HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

Recent Filings

• 06.02.2025 - EX-99.1 EX-99.1
• 06.02.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.30.2025 - EX-99.1 EX-99.1
• 05.23.2025 - EX-99.1 EX-99.1
• 05.23.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.13.2025 - EX-99.1 EX-99.1
• 04.24.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.24.2025 - EX-99.1 EX-99.1